(3R,4S)-4-Ethyl-1,3-Pyrrolidinedicarboxylic Acid 1-(Phenylmethyl) Ester Compd. With (Alphar)-Alpha-Methyl-1-Naphthalenemethanamine (1:1)

What Minimum Purity Can a Diastereomeric Salt Recrystallization Achieve for (S)-Naproxen?

Resolution of racemic 2-(6-methoxy-2-naphthyl)propionic acid (naproxen) into its therapeutically active (S)-enantiomer using this enantiopure salt (1.05 molar equivalents relative to the racemate) proceeds via a classical diastereomeric crystallization in a jacketed glass-lined reactor. The solubility difference of the resulting diastereomeric salts in a 85:15 (v/v) ethanol/water mixture at 70 °C followed by a controlled linear cooling ramp of 0.15 K/min to 12 °C is critical: a deviation in the cooling rate exceeding ±0.05 K/min triggers oiling-out of the less soluble salt, collapsing the chiral purity below 98.0%. FBRM (focused beam reflectance measurement) monitoring of the chord length distribution guides the addition of milled seed crystals (0.5% w/w of theoretical yield) at the metastable zone boundary (48–52 °C). The harvested diastereomeric salt is washed with cold ethanol, then dissociated with 2 M HCl and extracted into ethyl acetate; the organic phase yields (S)-naproxen with an enantiomeric excess of ≥99.5% after a single recrystallization. Compliance constants: the free acid conforms to the USP Naproxen monograph and Ph. Eur. 0763, residual elemental impurities are controlled under USP <232>/<233>, and the resolution process falls under ICH Q7 GMP guidelines for API intermediates. The terminal product manufactured directly from this stage is (S)-naproxen sodium USP, compacted into oral solid dosage forms. If the molar ratio exceeds 1.10, co-precipitation of the antipode salt increases the heavy metal burden from nickel-leached catalyst residues, necessitating an additional activated carbon treatment step that reduces overall yield by 4–7%.

The covalent immobilization of the single-enantiomer salt, specifically the (R)-amine/(R,R/S)-acid configuration, onto 5 µm spherical silica particles with a pore diameter of 100 Å (Kromasil KR100-5) yields a Pirkle-type chiral stationary phase (CSP) suitable for direct enantiomeric separation of β-blockers, benzoin derivatives, and profen racemates. The silica is first refluxed with 3-aminopropyltrimethoxysilane in anhydrous toluene to achieve an aminopropyl surface coverage of 3.2–3.5 µmol/m², confirmed by TGA weight loss. Thereafter, the chiral salt (2.5 g) dissolved in a 1:1 (v/v) mixture of anhydrous DMF and pyridine is activated with HOBt (1.3 eq.) and DIC (1.5 eq.), then stirred with the aminopropyl silica (5.0 g) under nitrogen for 14 h at ambient temperature. The resulting chiral selector density, determined by elemental analysis of nitrogen content, is controlled within 0.38–0.45 mmol/g. End-capping with trimethylchlorosilane (0.5 mL per gram of silica) minimises residual amino group interference. The modified silica is slurry-packed into a 250 × 4.6 mm ID stainless steel column using isopropanol at 35 MPa back pressure. Performance qualification follows USP General Chapter <621> and EP 2.2.46; the column must resolve racemic benzoin with a resolution Rₛ ≥ 2.0 using a mobile phase of n-hexane/isopropanol (90:10) at 1.0 mL/min and detection at 254 nm. The CSP lifetime exceeds 2,000 injections when operated at pH 3.5–7.0 and temperature ≤35 °C. Terminal product is the polished HPLC column accompanied by a quality control certificate referencing ASTM E682-92 retention metrics. This chromatographic tool underpins release testing for bulk drug enantiomeric purity in numerous ANDA submissions.

When a Rhodium/Chiral Acid Ion Pair Improves Enantioselectivity in Enamide Hydrogenation

The debenzylated form of the salt—obtained by hydrogenolytic cleavage of the 1-benzyl group using 5% Pd/C (wet, 50% water) in tetrahydrofuran at 0.35 MPa H₂ and 25 °C—yields (3R,4S)-4-ethylpyrrolidine-1,3-dicarboxylic acid, which serves as a chiral acid counterion during the rhodium-catalyzed asymmetric hydrogenation of N-acetyl dehydro-β-amino acid methyl esters. The catalyst is generated in situ by combining [Rh(COD)Cl]₂ (0.5 mol%) with (R)-BINAP (1.1 mol%) in methanol, followed by addition of the chiral diacid (0.55 mol% relative to the rhodium monomer) and triethylamine (1.2 eq.). The substrate-to-catalyst ratio is maintained at S/C = 500. Hydrogenation proceeds at 4.5 MPa H₂ and 50 °C in a Hastelloy autoclave; ex situ ³¹P NMR reveals that the chiral diacid displaces the chloride bridge, forming a cationic Rh-diphosphine complex with the carboxylate occupying an outer-sphere position, which has been observed to improve the enantiomeric excess from 92% to 99.3% for methyl (Z)-2-acetamido-3-(3,4-dimethoxyphenyl)acrylate. Downstream processing involves filtration over a celite pad to remove colloidal palladium, solvent swap to ethyl acetate, aqueous bicarbonate wash to extract the chiral diacid (recovered with 92% efficiency), and crystallisation of the (R)-β-amino ester. Residual palladium is monitored against USP <232>/<233> limits, and volatile impurities comply with ICH Q3C Class 2 solvent thresholds. The terminal product is a key chiral amine intermediate used in the synthesis of sitagliptin phosphate, subsequently converted into the final dosage form under FDA-approved GMP conditions. If the moisture content of the recycled chiral diacid exceeds 0.15%, the hydrogenation batch exhibits an induction period exceeding 90 min, which decreases the space-time yield below the economically viable threshold of 0.8 kg·L⁻¹·h⁻¹.

How Can Chiral Polyamide Membranes Achieve Enantioselective Permeation?

Interfacial polymerization of a diacyl chloride containing (3R,4S)-4-ethylpyrrolidine-1,3-dicarbonyl dichloride—prepared by reacting the debenzylated diacid with thionyl chloride—with piperazine on a polysulfone ultrafiltration support generates a thin-film composite membrane that exhibits stereoselective transport. The chiral diester monomer is incorporated at 1–2 mol% of the total acyl chloride mixture (the remainder being trimesoyl chloride and isophthaloyl chloride). Standardization of the fabrication follows ASTM D4194-03 for reverse osmosis membrane integrity and ISO 10993-1:2018 if the permeate contacts biological fluids. In a cross-flow cell operating at 1.0 MPa, an aqueous racemic propranolol hydrochloride feed (200 mg/L) and a pH 8.5 buffer produce an enantiomeric excess in the permeate of 14–18% preferring the (R)-isomer when the chiral diacid loading is 1.5 mol%. Permeance declines sharply from 7.5 L·m⁻²·h⁻¹·bar⁻¹ at 1.0 mol% to 2.2 L·m⁻²·h⁻¹·bar⁻¹ at 3.0 mol%, a consequence of increased cross-linking disrupting the nodular polyamide morphology. The downstream operation mode is a single-stage enrichment cascade followed by diastereomeric crystallization; the terminal product is (S)-propranolol hydrochloride meeting USP purity for sustained-release capsules. Long-term exposure of the membrane to residual chlorine levels exceeding 0.1 ppm causes irreversible loss of chiral recognition within 48 h.

Direct utilization of the neat enantiopure salt as a chiral ionic liquid—its melting point recorded by DSC at 87 °C with a glass transition at −32 °C—permits the L-proline-catalyzed asymmetric aldol addition of acetone to 4-nitrobenzaldehyde under solvent-free conditions while maintaining a high local chiral medium effect. The substrate is dissolved in the molten salt at a concentration of 0.5 mmol/mL, and L-proline is added at 15 mol%. The reaction mixture is stirred for 24 h at 25 °C under a nitrogen atmosphere within an environment where the relative humidity is maintained below 30%; moisture content above 0.5% w/w in the ionic liquid, as measured by Karl Fischer titration, reduces the diastereomeric ratio of the anti-product from 85:15 to 60:40. Post-reaction, the crude product is extracted with multiple portions of cold diethyl ether, and the ionic liquid phase is vacuum-dried (40 °C, 10 mbar) for direct reuse over five cycles without loss of enantioselectivity. Residual solvent analysis follows ICH Q3C and confirms ether levels below the 5000 ppm limit. The downstream processing sequence converts the aldol adduct into a β-hydroxy ketone building block for a second-generation renin inhibitor; this intermediate is purified by flash chromatography and crystallized to 99.7% chemical purity before entering a GMP step. Regulatory oversight for the ionic liquid’s composition and its degradation profile (no detectable amine release at 120 °C by headspace GC) is part of a Type II drug master file submission.

System Suitability Reference Standard for Pyrrolidine Ring-Containing API Compendial Methods

Recrystallization of the salt from ethyl acetate/n-hexane (7:3 v/v) using a stepwise temperature gradient (0.1 K/min from 55 °C to 2 °C) yields a crystalline solid with a final enantiomeric excess of 99.9%, confirmed by chiral HPLC against a calibration curve built from racemate-spiked samples. This material is milled under liquid nitrogen and vacuum-dried at 55 °C for 16 h to remove residual solvent below ICH Q3C Option 1 limits. A 0.1 mg/mL solution in acetonitrile serves as the system suitability preparation to evaluate resolution between the (3R,4S)-diastereomer and its (3S,4R)-antipode in a compendial HPLC method employing a cellulose tris(3,5-dimethylphenylcarbamate) column (250 × 4.6 mm, 5 µm). Compliance with ISO 17034:2016 for reference material producers and USP <11> reference standards is maintained; each batch is accompanied by a certificate of analysis reporting quantitative NMR purity, water content (Karl Fischer, <0.2%), and trace-level metal residues under USP <232>/<233>. The end-use of this standard is the release testing of a pyrrolidine-based active pharmaceutical ingredient intended for neuropathic pain management, where regulatory authorities require a system precision RSD for replicate injections of ≤1.0% and a resolution factor of ≥2.5 between the critical pair. Any exposure of the reference standard to relative humidity exceeding 40% during dispensing leads to hydrate formation that alters retention time by 0.7 min, invalidating the system suitability test.